Navigation Links
National Lung Cancer partnership
Date:2/21/2008

Madison, Wis. The National Lung Cancer Partnership announced today they are joining three distinguished organizations: the Lance Armstrong Foundation, the Oncology Nursing Society Foundation and the International Association for the Study of Lung Cancer in continuing the mission to increase opportunities for lung cancer researchers by co-sponsoring new lung cancer research grants.

Lung cancer is the leading cancer killer of men and women in the United States but it receives less research funding than almost any other cancer.

If we are going to conquer this disease we need to bring new researchers and specialized professionals like oncology nurses into the field, said Joan Schiller, M.D., president of the National Lung Cancer Partnership, deputy director of Simmons Comprehensive Cancer Center and division director of Hematology/Oncology at the University of Texas-Southwestern Medical Center, Dallas. At the same time, we need to add to research that will help us identify best practices when it comes to helping survivors live better lives.

The Lance Armstrong Foundation and the National Lung Cancer Partnership will co-sponsor a Young Investigator survivorship grant, which will fund lung cancer survivorship research projects, such as an investigation of access to quality survivor care and services for lung cancer survivors.

National Lung Cancer Partnership and the Oncology Nursing Society Foundation are co-sponsoring the Lung Cancer Nursing Research Grant, which will support research addressing lung cancer and focusing on areas that will advance the science and practice of oncology nursing, such as research into nursing-sensitive patient outcomes.

The third new grant in conjunction with the International Association of the Study of Lung Cancer (IASLC), will provide research funding for the training of young investigators interested in lung cancer research as well as require recipients to take one course per year wi
'/>"/>

Contact: Sara Conley
sconley@pcipr.com
312-558-1770
National Lung Cancer Partnership
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Logistical information for the 2008 International Stroke Conference
2. China Dongsheng International Announces Fiscal Year 2008 Second Quarter Financial Results
3. ASA International Stroke Conference 2008
4. DATATRAK International Management to Host Conference Call on February 26, 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007
5. Florida Tissue Services Receives National Accreditation
6. ORBIS Internationals Flying Eye Hospital Returns to Myanmar
7. Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List
8. Fox Hill Senior Condominium Development Thrives During National Housing Slump
9. AUDIO from Medialink and Pfizer: February is National Heart Month
10. National Magazine Ranks Highmark Best Green Information Technology Company in the Nation
11. National Council on Disability Bulletin, January 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 1The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 2The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 1Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 2Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 4Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 5AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 1AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 3AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 4